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Abstract
Introduction. The aim of this study was to estimate the prevalence and assess patient-re-
lated determinants of polypharmacy in the general population of the Italian area around 
Udine.
Materials and methods. A retrospective cohort study was conducted using administra-
tive databases: drug prescriptions, hospital discharges, ambulatory care prescriptions, ex-
emptions from medical charges. Various definitions of polypharmacy were adopted (co-
prescription of multiple medications, use of multiple medications for overlapping time 
periods). The role of patient’s characteristics on polypharmacy was assessed through 
regression analyses.
Results. In 2017, 63.7% of the general population received at least one drug prescrip-
tion. 25 218 persons were co-prescribed ≥ 5 medications at least once. The prevalence of 
co-prescriptions among persons ≥ 65 years was 31.7%. 20 793 persons used ≥ 60 DDDs 
of ≥ 5 medications. The prevalence of all these phenomena was much higher in the el-
derly than in children and adults. The number of comorbidities significantly affected all 
types of polypharmacy.
Conclusions. In this area, the prevalence of polypharmacy is high, particularly among 
the elderly. Age and comorbidities significantly affect the risk. Further research will aim 
at evaluating the health effects and appropriateness of polyphamacy.  
INTRODUCTION
As a consequence of multimorbidity, which is com-
mon among older persons and whose frequency is ex-
pected to rise because of population ageing [1, 2], the 
use of multiple medicines is widespread. For example, 
a prevalence survey in 17 European countries reported 
that from 26.3 to 39.9% of the population ≥ 65 years of 
age responded that they take at least five different drugs 
on a typical day, including prescribed medication, over-
the-counter medications, and dietary supplements [3]. 
The use of multiple medications by a patient, known as 
polypharmacy, may be necessary in many cases; nonethe-
less, it is associated with both adverse outcomes on the 
patients [4], economic costs for society [5, 6], and, in 
the primary care setting, increased medication errors [7]. 
Despite the relevance of this phenomenon for all the 
above-mentioned issues, a recent systematic review 
highlighted that there is no uniform definition of poly-
pharmacy [8]: the analysis of more than 100 articles re-
vealed that there were a total of 138 definitions, 80.4% 
of which were numerical only and an additional 10.7% 
also specified either a duration of therapy or healthcare 
setting, the remaining being descriptive definitions. The 
most common definition, used by almost half of the ar-
ticles, was numerical (five or more medications daily) 
[8]. Among descriptive definitions, some addressed co-
prescribing or simultaneous use [8].
A study conducted in Rome from health administra-
tive databases confirmed that polypharmacy is a rele-
vant issue in Italy, related to age and comorbidities; the 
study also showed that prevalence estimates changed 
using different algorithms [9].
The objective of this research was to estimate the 
prevalence and to assess patient-related determinants of 
polypharmacy in the Northeastern Italian area served by 
the Azienda Sanitaria Universitaria Integrata di Udine 
(ASUIUD), 251 838 inhabitants as of January 1, 2017, 
using the administrative health databases of ASUIUD.
METHODS
This retrospective cohort study was based on the 
health administrative data of ASUIUD. In particular, 
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the drug prescription database, the hospital discharge 
database, the ambulatory care prescriptions database, 
and the database of exemptions from medical charges, 
which includes patients who receive free medications or 
outpatient care because of certified chronic conditions 
defined by the Italian Ministry of Health and which 
may help identifying patients with a certain disease 
since each disease or group of diseases is associated 
with a specific national code [10, 11]. The databases 
are completely anonymous, nonetheless, they can be 
linked with each other at the individual patient level 
through a stochastic key which is univocally attributed 
to each subject.  In-hospital medications were not in-
cluded in this analysis since medications administered 
during hospital stay are not recorded electronically at 
the individual level. 
All the analyses were referred to the year 2017. Dif-
ferent definitions of polypharmacy were adopted: 1) 
prescriptions of ≥ 5 different medications (i.e., different 
7-digit Anatomical Therapeutic Chemical (ATC) codes 
[12]) on exactly the same date (i.e., “co-prescriptions”); 
2) use of ≥ 5 different medications for ≥ 60 defined daily 
doses (DDDs) in the year; and 3) use of ≥ 5 different 
medications with > 30, >60, and > 90 overlapping days 
of theoretical medication coverage in the year, where 
medication coverage was estimated adding the pre-
scribed DDDs to the date of medication retrieval from 
the pharmacy. The analyses were stratified by sex and 
age category (0-14 years, pediatric; 15-64, adult; 65-79, 
younger elderly; ≥ 80, older elderly).  
To assess the influence of comorbidities on polyphar-
macy, the number of different types of comorbidity per 
patient was assessed, applying algorithms developed by 
the Italian Local Health Agency of Brescia [13] to the 
health administrative data of ASUIUD (hospital dis-
charge records, medication prescriptions, ambulatory 
care prescriptions, and exemptions from medical charg-
es). Comorbidity types identified by the algorithms in-
clude chronic lung diseases, chronic heart failure, other 
cardiovascular diseases (including hypertension), diabe-
tes mellitus, disorders of lipid metabolism, HIV, chronic 
kidney disease, rare diseases, cancer, digestive system 
diseases, autoimmune, endocrine diseases, neurological 
diseases, transplanted organs. The number of different 
comorbidities was assessed among patients with medi-
cation co-prescriptions. Among all patients with at least 
one drug prescription in 2017, the association between 
number of comorbidities and the likelihood of co-pre-
scriptions of ≥ 5 drugs was assessed through multivari-
ate logistic regression adjusting for the potentially con-
founding effect of patient’s sex and age category. The 
association was assessed trough the odds ratio (OR) 
with 95% confidence intervals (95% CI).
In addition, the association between the number of 
comorbidities and both a) the number of different med-
ication used for ≥ 60 DDDs in the year, among subjects 
using ≥ 60 DDDs of at least one medication, and b) the 
number of days of overlapping coverage among subjects 
with ≥ 5 medications with at least one day of overlap, 
were assessed through two linear regression models, 
also adjusting for the potentially confounding effect of 
patient’s sex and age category. The associations were ex-
pressed by the beta coefficients; results with p-value < 
0.05 were considered statistically significant.
Finally, to investigate other characteristics of the pop-
ulation potentially associated with polyphamacy, we as-
sessed the proportion of subjects exempt from medical 
charges due to low family income (evaluated through 
an indicator of equivalent economic situation  called 
ISEE) among those fulfilling the 3 above-listed defini-
tions of polypharmacy. 
All the analyses of the present study were conducted 
using SAS v9.4 (SAS Institute Inc. Cary, NC, USA). 
Compliance with ethical standards
Since this analysis was based on anonymous admin-
istrative data, patient informed consent could not be 
obtained and Ethical Committee approval was not re-
quired in Italy.
RESULTS
In 2017, 3 105 481 prescriptions were retrieved from 
the prescription database. Of all subjects living in the 
ASUIUD area, 160 465 (63.7%) received ≥ 1 medica-
tion prescription in 2017: 55.8% were females; 8.5% 
were children, 54.5% adults, 25.0% younger elderly, and 
10.9% older elderly. In the year of study, 25 218 patients 
received ≥ 1 co-prescription of ≥ 5 different medications 
(10.0% of the population), for a total of 82 044 episodes 
of co-prescription of ≥ 5 medications (polypharmacy 
definition 1). As shown in Table 1, the prevalence of co-
prescriptions is much higher in the elderly than among 
adults. Overall, the proportion of population ≥ 65 years 
of age who were co-prescribed ≥ 5 medications at least 
one in 2017 was 31.7%. The monthly distribution of the 
number of co-prescriptions of ≥ 5 medications by age 
category did not show any specific pattern (Figure 1). 
The 5 most commonly groups of medications found in 
such co-prescriptions (not necessarily in the same co-
prescription) by age group are shown in Table 2. The ob-
served different co-prescription patterns were 66 206, 
with frequency ranging from 1 to 119 cases (available as 
Supplementary materials). Of the 5 most common co-
prescription patterns, all but one included one drug for 
peptic ulcer and gastro-esophageal reflux disease, one 
antithrombotic agent, and three medications acting on 
the cardiovascular system, as follows:
- A02BC02 + B01AC06 + C07AB07 + C09AA05 + 
C10AA05 (N=119)
- A02BC02 + B01AC06 + C07AB02 + C09AA05 + 
C10AA05 (N=76)
- A02BC02 + B01AC06 + C03CA01 + C07AB07 + 
C09AA05 (N=30)
- B01AC06 + C07AB07 + C09AA05 + C10AA05 + 
C10AX09 (N=25)
- A02BC02 + B01AC06 + C08CA01 + C09AA05 + 
C10AA05 (N=24)
In 2017, 20 793 patients (8.2%) used ≥ 60 DDDs 
of ≥ 5 medications (polypharmacy definition 2): 1 in the 
age group 0-14 (0.003%), 3407 in the age group 15-64 
(2.2%), 10 752 in the group 65-79 (24.1%), and 6633 in 
the group ≥ 80 (34.3%). The median number of comor-
bidities for patients with co-prescriptions of ≥ 5 medi-
cations was 0 among children (interquartile range 0-2) 
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and 3 in all other age groups (interquartile range 2-4). 
The number of overlapping days covered with ≥ 5 dif-
ferent medications (polypharmacy definition 3) is illus-
trated in Table 3. More than 5% of the whole population 
had ≥ 5 medications overlapping for > 90 days in a year. 
The prevalence of such an important overlap was much 
higher in the elderly groups. The prevalence of overlaps 
of ≥ 5 medications was slightly more frequent among 
males (Table 4). 
Of all subjects living in the ASUIUD area, those 
with at least one chronic condition were 2.5% in the 
age group 0-14, 28.3% in the age group 15-64, 80.8% 
in the age group 65-79, and 99.3% among persons ≥ 80 
years of age. Among children, there was no one with 
≥ 5 comorbidities; on the other hand, the coexistence 
of 5 or more long-term conditions was found in 0.3% 
of the population 15-64, in 3.7% of those 65-79, and 
in 5.0% of those ≥ 80 years of age. Table 5 shows the 
association of the number of comorbidities with the 
various forms of polytherapy. Among subjects with at 
Table 1
Prevalence of co-prescriptions of ≥ 5 medications in the population of the Azienda Sanitaria Universitaria Integrata di Udine, Italy, 
2017
Sex Age category N of patients with 
co-prescriptions
Population Prevalence (%) Total N of  
co-prescriptions
F 0-14 6 15 222 0.04 6
F 15-64 2369 79 510 2.98 5926
F 65-79 6047 24 276 24.91 18 825
F ≥ 80 5080 12 804 39.68 17 097
M 0-14 6 15 693 0.04 6
M 15-64 2551 77 454 3.29 7891
M 65-79 6281 20 334 30.89 22 288
M ≥ 80 2878 6538 44.02 10 005
Total 25 218 25 1831 10.01 82 044
Figure 1
Number of co-prescriptions of ≥ 5 medications by month and age category, Azienda Sanitaria Universitaria Integrata di Udine, 
Italy, 2017.
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least one prescription in 2017, the likelihood of being 
co-prescribed ≥ 5 medications increased by more than 3 
times for each additional comorbidity. Among subjects 
with prescriptions of ≥ 60 DDDs of at least one drug in 
the year, adjusting for the confounding effect of sex and 
age, a patient is likely to be prescribed ≥ 60 DDDs of 
one additional medication for each additional comor-
bidity. Also, each additional comorbidity increases the 
average coverage with ≥ 5 medications simultaneously 
by 27 days.
Among all subjects with co-prescriptions of ≥ 5 
medications (polypharmacy definition 1), no one was 
exempted from medical charges due to low income in 
the age group 0-14, 1.6% had such an exemption in the 
group 15-65, 0.1% in the group 65-79, and < 0.1% in 
the group ≥ 80 years of age. Among those using ≥ 5 
different medications for ≥ 60 DDDs in the year (poly-
pharmacy definition 2), no one had exemptions due to 
low family income in the age group 0-14, 1.2% had such 
an exemption in the group 15-64, 0.1% in the group 
Table 2
The five most common groups of medications found in co-prescriptions of ≥ 5 medications by age category, Azienda Sanitaria 
Universitaria Integrata di Udine, Italy, 2017
Age 
category
4-digit
ATC code
Medication 
group
N of 
co-prescriptions 
% of all 
co-prescriptions
0-14a R03A adrenergics, inhalants 10 83.3
H02A corticosteroids of systemic use 9 75.0
R03B drugs for obstructive airway diseases, 
inhalants, other than adrenergics
9 75.0
J01C penicillins 6 50.0
15-64 C10A lipid modifying agents 8580 62.1
B01A antithrombotic agents 8165 59.1
A02B drugs for peptic ulcer and gastro-
esophageal reflux disease
7919 57.3
C07A beta blocking agents 6025 43.6
A10B blood glucose lowering drugs, excl. 
insulins
4264 30.9
65-79 B01A antithrombotic agents 27 611 67.2%
C10A lipid modifying agents 24 550 59.7%
A02B drugs for peptic ulcer and gastro-
esophageal reflux disease
23 074 56.1%
C07A beta blocking agents 18 528 45.1%
A10B blood glucose lowering drugs, excl. 
insulins
12 784 31.1%
≥ 80 B01A antithrombotic agents 19 106 70.5%
A02B drugs for peptic ulcer and gastro-
esophageal reflux disease
16 565 61.1%
C07A beta blocking agents 11 872 43.8%
C10A lipid modifying agents 10 730 39.6%
C03C high-ceiling diuretics 8809 32.5%
aonly the first 4 medication groups are shown since several others were equally frequent
Table 3
Overlapping days covered with ≥ 5 different medications in the population of the Azienda Sanitaria Universitaria Integrata di 
Udine, Italy, 2017
Overlap
(days)
N Prevalence (%)
00-14 15-64 65-79 ≥ 80 Total 00-14 15-64 65-79 ≥ 80 Total
≤ 30 91 6444 7320 3680 17535 0.29 4.11 16.41 19.03 6.96
31-60 7 1680 3198 2070 6955 0.02 1.07 7.17 10.70 2.76
61-90 2 955 2291 1504 4752 0.01 0.61 5.14 7.78 1.89
> 90 10 2384 7091 4244 13729 0.03 1.52 15.90 21.94 5.45
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65-79 and 0.1% in the group ≥ 80 years of age. Among 
patients with an overlap of ≥ 5 medications lasting > 
30 days (from polypharmacy definition 3), the proportion 
of those with exemption from medical charges due to 
low family income was 0 among children, 1.4% among 
subjects 15-64, 0.1% among both subjects 65-79 and 
subjects ≥ 80 years of age.     
DISCUSSION
This research illustrated various prescriptive issues 
related to polypharmacy in the general population of a 
Northern Italian area using health administrative data-
bases. These results are not affected by sampling error, 
selection bias, or recall bias. In fact, the data cover the 
entire population and are collected for administrative 
purposes in an objective way. 
This research showed that polypharmacy is by far 
more common among the elderly, especially those ≥ 
80 years of age, than among adults, irrespective of the 
definition of polypharmacy. Not only are 31.7% of the 
elderly co-prescribed ≥ 5 medications at least one in a 
year, but more than 15% of younger elderly and more 
than 20% of older elderly have an overlapping use of ≥ 5 
medications for more than 90 days in a year. 
As expected, the medications that were most fre-
quently involved in polypharmacy differed depending 
on the age group. Among children, medications were 
inhalants for obstructive airway disease, antibiotics 
and systemic corticosteroids; among adults and elderly 
patients, drugs for peptic ulcer and gastro-esophageal 
reflux disease, antithrombotic agents, antihypertensive 
medications, and lipid modifying agents were the most 
frequently co-prescribed.
In Italy, only few studies had previously been con-
ducted on polypharmacy in the outpatient setting 
among the general population. One of those studies 
was conducted in the Italian Region Friuli Venezia Gi-
ulia [14], which includes our study area. That study, an-
alyzing polypharmacy in the hospital, general practice, 
and long term care facility settings, showed a very high 
prevalence of polypharmacy in the elderly population, 
as high as 57.7% of patients being co-prescribed 5-9 
drugs and 9.7% being prescribed 10 or more. However, 
such estimates were based on a one-week point-prev-
alence survey which might have not been representa-
tive of the general prescription habits either because of 
random error or because of systematic error due to the 
possible existence of seasonal variations, of bias in the 
selection participating GPs, or of bias in the selection of 
the surveyed patients.  
Another study was conducted [15] in the Emilia-
Romagna Region, based on the analysis of outpatient 
drug prescriptions. The proportion of elderly patients 
exposed to overlapping treatment with ≥ 5 medications 
for ≥ 1 day was 39.4%. The most frequent groups of 
drugs involved in polypharmacy in that study were the 
same that characterized polypharmacy in the elderly 
population of the area of Udine.  
The European data based on data from the large 
Survey of Health, Ageing and Retirement in Europe 
Table 4
Prevalence of overlapping days covered with ≥ 5 different medications in the population of the Azienda Sanitaria Universitaria 
Integrata di Udine, Italy, 2017, by sex
Overlap
(days)
Females (% of population) Males (% of population)
0-14 15-64 65-79 ≥ 80 Total 0-14 15-64 65-79 ≥ 80 Total
≤ 30 0.18 4.72 17.84 19.80 8.08 0.41 3.48 14.70 17.51 5.74
31-60 0.03 1.06 7.05 10.36 2.95 0.02 1.08 7.31 11.36 2.56
61-90 0.01 0.51 4.65 7.44 1.88 0.01 0.71 5.71 8.44 1.89
> 90 0.03 1.08 12.01 19.32 4.75 0.03 1.97 20.53 27.07 6.23
Table 5
Association between number of comorbidities and likelihood of co-prescription of ≥ 5 medications among all subjects with at 
least one drug prescription, number of different medications with ≥ 60 DDDs prescribed in one year among users of ≥ 60 DDDs of 
at least one medication, and number of overlapping days of coverage with ≥ 5 medications in one year among users of ≥ 5 medi-
cations for at least one overlapping day in the Azienda Sanitaria Universitaria Integrata di Udine, Italy, 2017
Co-prescription 
of ≥ 5 medications
N of medications 
with ≥ 60 DDDs 
N of overlapping days  
of coverage  
with ≥ 5 medications
Variable OR 95CI Beta coefficient p-value Beta 
coefficient
p-value
Sex (F vs M) 0.75 0.73-0.78 -0.4144 < 0.0001 -21.38 < 0.0001
Age (0-14 vs 15-64) 0.07 0.04-0.13 0.1258 0.0579 16.25 0.0579
Age (65-79 vs 15-64) 2.70 2.29-2.82 0.6837 < 0.0001 10.71 0.0107
Age (≥ 80 vs 15-64) 5.44 5.18-5.72 1.1888 < 0.0001 18.35 < 0.0001
N of comorbidities (continuous) 3.44 3.39-3.50 1.1184 < 0.0001 27.42 < 0.0001
Francesca Valent
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
238
(SHARE) project, Wave 6, found a prevalence of “use 
of at least 5 different drugs on a typical day” among 
participants ≥ 65 years ranging from 26.3 to 39.9% [3]. 
In particular, in Italy the prevalence was 32.9% (95% 
CI: 32.3-33.5%), increasing with age category from 
26.4% in subjects 65-74 to 45.1% in those ≥ 85 years, 
and slightly higher in males (33.2%) than in females 
(32.5%). Number of chronic diseases was also associ-
ated with polypharmacy, as was in the present study.  
Due to the absence of social and lifestyle information 
on the health administrative data of the ASUIUD, the 
association of those factors on the prevalence of poly-
therapy could not be assessed, as done in the European 
survey [3]. Among subjects with polypharmacy in the 
area of Udine, only a very small proportion had obtained 
an exemption from medical charges because of low fami-
ly income: from little more than 1% in the population 15-
64 years of age to less than 1% in the other age groups. 
However, these data should not be interpreted as a lack 
of association between low income and polypharmacy. 
In fact, not all economically disadvantaged citizens apply 
for such an exemption, especially if they are already enti-
tled to exemptions because of chronic conditions or civil 
invalidity [10, 11]. On the other hand, the present study 
confirmed that prevalence of polypharmacy increases 
with increasing age and number of comorbidities, as 
shown also by Fano et al. [9], exposing patients who are 
fragile per se to the additional health risks from polyphar-
macy adverse effects and inappropriate prescribing [14]. 
These results indicate a situation which deserves inter-
ventions to address polypharmacy. 
In addition, to better define the impact of polyphar-
macy on the population health of ASUIUD, a new co-
hort analysis of administrative data could be conducted 
to compare  health outcomes of patients with and with-
out polypharmacy or with different levels of polyphar-
macy, taking into account demographic factors and co-
morbidity level.  
This study has some limitations, mainly due to the ad-
ministrative nature of data. First, in the analyses of the 
long term use of multiple medications the DDDs were 
used to estimate duration, however the DDDs may not 
accurately reflect the actual prescribed doses [16], thus 
durations might have been misestimated in some cases. 
Then, as in all studies where the medication is not di-
rectly administered by the researcher, there is no guar-
antee that the drug has been assumed, or assumed as 
prescribed, by the individual. In addition, intake of over-
the-counter medications could not be considered (now 
including frequently used medications such as treat-
ments for gastroesophageal reflux disease), suggesting 
that the actual prevalence and severity of polypharmacy 
might be even greater than our estimates. Further, no 
information was available on socioeconomic character-
istics of subjects other than exemptions from medical 
charges released because of low family income, thus 
leaving potential associations between social factors 
and polypharmacy unexplored. Finally, there are cases 
where co-prescribing multiple medications is appropri-
ate, but this analysis did not assess appropriateness. 
The information on all the co-prescription patterns was 
available, but with over 80 000 co-prescription episodes 
in 2017, the observed different co-prescription patterns 
were more than 65 000 and an individual evaluation of 
each one was unfeasible.
Since the vast majority of the elderly population and 
almost 30% of the adult population in our area is affected 
by long-term conditions, with 5% of the population ≥ 80 
having 5 or more comorbidities, polypharmacy may be 
the obvious consequence of the justified attempt to con-
trol chronic and often multiple diseases. Nonetheless, 
polypharmacy may be more harmful than beneficial for 
some patients, due to the possibility of drug-drug inter-
actions [17], that may even result in toxicity or treatment 
failure [18, 19]. In addition, most clinical trials are con-
ducted and most clinical guidelines are developed as if 
patients have a single condition; clinical recommenda-
tions generally do not consider the possible cumulative 
impact that multiple guidelines may have on a single pa-
tient [20]. Clinical guidelines taking into account multi-
morbidity and polypharmacy, then, are needed [21].  
Despite not being able to assess appropriateness and 
the potential for drug-drug interactions, this study de-
scribed the high prevalence of polypharmacy in the gen-
eral population of ASUIUD, including children, high-
lighted classes of medications that are more commonly 
involved in co-prescribing, and identified that the elder-
ly and patients affect by multimorbidity are particularly 
exposed to this phenomenon and the related health 
risks. Further research which will help clarify the actual 
impact of polypharmacy on health outcomes is feasible 
and will be conducted in this area. Information of GPs 
on this issue should also be kept as a priority.  
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